ExeVir Bio
PrivateLast Round
Grant
Jun 28, 2023
Total Funding Raised
$108.78M
Company Overview
ExeVir Bio operates in Healthcare & Life Sciences and is based in Belgium. Its latest recorded funding round was a Grant round in June 2023.
ExeVir Bio is a biotechnology company that develops single-domain antibody-based therapies for the treatment and prevention of infectious diseases.
Sector
Healthcare & Life Sciences
Verticals
Biotechnology, Drug Discovery, Clinical Trials
Business Model
B2B
Customer Profile
Services & Consulting
AI Layer
Non-AI
Historical Pricing
Historical view of private secondary pricing and transaction trends.
ExeVir Bio Comparables
Compare ExeVir Bio with similar companies based on industry and business-model similarity.
| Company | Similarity | Market Cap |
|---|---|---|
| DiosCURE Therapeutics SE | 89% | |
| Cerberus Therapeutics | 82% | |
| Invivyd | 79% |
For institutional investors. Book with your work email.
ExeVir Bio Funding Rounds
Historical fundraising activity
| Round | Date | Amount Raised | Valuation | Investors | Sources |
|---|---|---|---|---|---|
| Grant | Jun 28, 2023 | ||||
| Debt | Dec 14, 2022 | ||||
| Grant | Jul 13, 2021 | ||||
| Series A | Mar 16, 2021 | ||||
| Series A | Jul 28, 2020 |
For institutional investors. Book with your work email.
Key People
Founding team and executive leadership
For institutional investors. Book with your work email.
ExeVir Bio Investors
Notable investors and investment history
| Investor | Rounds |
|---|---|
| UCB Ventures | Series A |
| Federal Holding and Investment Company | Series A |
| Sopartec | Series A |
| Noshaq | Series A |
| Fund+ | Series A |
| Société Régionale d'Investissement de Wallonie | Series A |
| UCB Ventures | Series A |
For institutional investors. Book with your work email.
Market signals
Structured signals derived from secondary market and firmographic data.
- Jun 28, 2023
$1.74M grant received from VLAIO.
- Dec 14, 2022
$27M round from European Investment Bank Group.
For institutional investors. Book with your work email.
ExeVir Bio Filings
Explore SEC and related filing metadata, where available.
| Type | Date | Amount Offered | Amount Sold | Filing | Pages | Download |
|---|
Filing documents are not displayed on this public page. Request access to learn about available coverage.
Book a demoFor institutional investors. Book with your work email.
Frequently Asked Questions
Common questions about ExeVir Bio's valuation, stock price, and market status.
Is ExeVir Bio a public or private company?
ExeVir Bio is a private company.
What is the current stock price of ExeVir Bio?
ExeVir Bio is a private company, so its shares have no public market price. Caplight tracks ExeVir Bio's secondary market activity and provides MarketPrice™ estimates of its share price to Caplight users.
How much is ExeVir Bio worth (valuation)?
Valuation information for ExeVir Bio is not publicly available.
Can I buy ExeVir Bio stock?
ExeVir Bio shares may be available on secondary markets subject to transfer restrictions. Caplight facilitates secondary market transactions for accredited investors.
When was ExeVir Bio's last funding round?
ExeVir Bio's most recent funding round was Grant on June 28, 2023.
Who are the main investors in ExeVir Bio?
Key investors in ExeVir Bio include Fund+.
Will ExeVir Bio IPO soon?
No public IPO plans have been announced for ExeVir Bio.
How can I track ExeVir Bio secondary market activity?
Caplight tracks bids, offers, and trades in ExeVir Bio's shares on secondary markets.